Skip to main content
. 2022 Mar 30;23(7):3818. doi: 10.3390/ijms23073818

Figure 5.

Figure 5

EGFR alterations and survival in H&N cancer patients curated in the cBioPortal for Cancer Genomics. Patients who carry EGFR mutations and/or amplifications demonstrate a significantly briefer overall (A) and progression-free survival (B) than patients with unaltered EGFR. EGFR mutations are suggestively associated with disease-specific (C) and progression-free survival (D). EGFR genomic and clinical data were visualized, analyzed, and downloaded from the cBioPortal for Cancer Genomics (https://www.cbioportal.org; accessed on 19 March 2022 [22,23]).